UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): April 2, 2013
CATALYST PHARMACEUTICAL PARTNERS, INC.
(Exact Name Of Registrant As Specified In Its Charter)
Delaware | 001-33057 | 76-0837053 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
355 Alhambra Circle Suite 1500 Coral Gables, Florida |
33134 | |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (305) 529-2522
Not Applicable
Former Name or Former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 | Other Events |
On April 2, 2013, the Company issued a press release announcing its results of operations for the fourth quarter and the year ended December 31, 2012. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits |
99.1 | Press release issued by the Company on April 2, 2013. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Catalyst Pharmaceutical Partners, Inc. | ||
By: | /s/ Alicia Grande | |
Alicia Grande | ||
Vice President, Treasurer and CFO |
Dated: April 2, 2013
3
Exhibit 99.1
NEWS RELEASE | FOR IMMEDIATE RELEASE | |
For Further Information Contact: | ||
Patrick J. McEnany | Melody Carey | |
Catalyst Pharmaceutical Partners | Rx Communications Group | |
Chief Executive Officer | Co-President | |
(305) 529-2522 | (917) 322-2571 | |
pmcenany@catalystpharma.com | mcarey@rxir.com |
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-end 2012
Financial Results
CORAL GABLES, FL, April 2, 2013 Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders, today reported financial results for the fourth quarter and year ended December 31, 2012.
Patrick J. McEnany, CEO of Catalyst, commented, 2012 was a very challenging and yet transformational year for our company. Clearly the Catalyst team was very disappointed with the results of our Phase IIb clinical trial for CPP-109 as a potential treatment for cocaine addiction. We had high expectations to be able to deliver the first effective drug therapy for this horrific, intractable disease. We want to thank all the patients, patients families, physicians, investigators and our partner, the National Institute on Drug Abuse, for their support and involvement in this project.
Mr. McEnany continued, On the bright side, during the fourth quarter of 2012 we completed a strategic alliance with BioMarin Pharmaceutical Inc., where we acquired the North American rights to Firdapse, a late stage Phase III program to treat Lambert-Eaton Myasthenic Syndrome, (LEMS), a rare autoimmune, neuromuscular disease with the primary symptoms of progressive muscle weakness and fatigue. Also, as part of the transaction, BioMarin made a $5 million equity investment in Catalyst, resulting in a 16.6% stake in the Company. CPP-115 has successfully completed a Phase Ia, first-in-man study. The near-term advancement of CPP-115 for the Infantile Spasm indication will require a strategic partner or grant funding. We have recently augmented our management team in the areas of regulatory and clinical operations and expect to add a senior commercial operations person in the second quarter of this year. Finally, we ended 2012 with a healthy balance sheet and have sufficient cash and cash equivalents, certificates of deposits and short-term investments to fund our research and development activities for Firdapse and other operations through the first quarter of 2014.
Financial Results
For the year ended December 31, 2012, Catalysts net loss was $4,076,386, or $0.14 per basic and diluted share, compared to a net loss of $6,391,062, or $0.29 per basic and diluted share, in the prior year. Research and development expenses for 2012 were $2,659,597, compared to $3,383,965 in 2011. General and administrative expenses for 2012 were $2,561,543, compared to $2,698,174 in 2011. Change in fair value of warrants liability, a non-cash item, resulted in a gain of $1,129,778 for 2012, as compared to a loss of $319,908 for 2011.
For the fourth quarter of 2012, Catalysts net loss was $76,585, or $0.00 per basic and diluted share, compared to a net loss of $2,351,934, or $0.10 per basic and diluted share, for the same period in 2011.
At December 31, 2012, Catalyst had cash and cash equivalents, certificates of deposit and short-term investments of $15.4 million and no debt. Catalyst believes that its existing cash and investments will be sufficient to meet its projected operating requirements through the first quarter of 2014.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc., is a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourettes Syndrome. Catalysts lead candidate, Firdapse for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourettes Syndrome, and movement disorders associated with the treatment of Parkinsons Disease.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Companys actual results in future periods to differ materially from forecasted results. A number of factors including whether the Phase III trial will be successful, whether the Phase III trial will be completed on the expected timeline, whether any of the Companys product candidates will ever be approved for commercialization, as well as those factors described in the Companys filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Companys filings with the SEC are available from the SEC, may be found on the Companys website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.
# # #
Page 2
CATALYST PHARMACEUTICAL PARTNERS, INC.
(a development stage company)
STATEMENTS OF OPERATIONS
Year Ended December 31, | ||||||||||||
2012 | 2011 | 2010 | ||||||||||
Revenues government grant |
$ | | $ | | $ | 488,958 | ||||||
Operating costs and expenses: |
||||||||||||
Research and development |
2,659,597 | 3,383,965 | 2,306,781 | |||||||||
General and administrative |
2,561,543 | 2,698,174 | 2,206,358 | |||||||||
|
|
|
|
|
|
|||||||
Total operating costs and expenses |
5,221,140 | 6,082,139 | 4,513,139 | |||||||||
Loss from operations |
(5,221,140 | ) | (6,082,139 | ) | (4,024,181 | ) | ||||||
Interest income |
14,976 | 10,985 | 17,858 | |||||||||
Change in fair value of warrants liability |
1,129,778 | (319,908 | ) | | ||||||||
|
|
|
|
|
|
|||||||
Loss before income taxes |
(4,076,386 | ) | (6,391,062 | ) | (4,006,323 | ) | ||||||
Provision for income taxes |
| | | |||||||||
|
|
|
|
|
|
|||||||
Net loss |
$ | (4,076,386 | ) | $ | (6,391,062 | ) | $ | (4,006,323 | ) | |||
|
|
|
|
|
|
|||||||
Net loss per share - basic and diluted |
$ | (0.14 | ) | $ | (0.29 | ) | $ | (0.22 | ) | |||
Weighted average shares outstanding basic and diluted |
30,033,108 | 21,728,292 | 18,580,223 |
Page 3
CATALYST PHARMACEUTICAL PARTNERS, INC.
(a development stage company)
CONDENSED BALANCE SHEETS
December 31, | ||||||||
2012 | 2011 | |||||||
ASSETS | ||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 1,409,939 | $ | 6,029,067 | ||||
Certificates of deposit |
6,502,825 | | ||||||
Short-term investments |
7,504,444 | | ||||||
Prepaid expenses |
1,309,470 | 199,116 | ||||||
|
|
|
|
|||||
Total current assets |
16,726,678 | 6,228,183 | ||||||
|
|
|
|
|||||
Property and equipment, net |
53,679 | 12,186 | ||||||
Deposits |
8,888 | 8,888 | ||||||
|
|
|
|
|||||
Total assets |
$ | 16,789,245 | $ | 6,249,257 | ||||
|
|
|
|
|||||
LIABILITIES AND STOCKHOLDERS EQUITY | ||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 1,365,663 | $ | 263,934 | ||||
Accrued expenses and other liabilities |
281,002 | 569,867 | ||||||
|
|
|
|
|||||
Total current liabilities |
1,646,665 | 833,801 | ||||||
Accrued expenses and other liabilities, non-current |
21,878 | 9,518 | ||||||
Warrants liability, at fair value |
498,587 | 1,645,240 | ||||||
|
|
|
|
|||||
Total liabilities |
2,167,130 | 2,488,559 | ||||||
Total stockholders equity |
14,622,115 | 3,760,698 | ||||||
|
|
|
|
|||||
Total liabilities and stockholders equity |
$ | 16,789,245 | $ | 6,249,257 | ||||
|
|
|
|
Page 4